Search clinical trials for: Rituximab-Bendamustine

Total 3305 results

Hoffmann-La Roche

Active, not recruiting

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO)

Chronic Lymphocytic Leukemia (CLL)

United States, Italy, Australia, Spain, France
Artiva Biotherapeutics, Inc.

Recruiting

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, United States, Spain, Belgium, Austria, Czechia, Australia, Italy, Japan, Hungary, United Kingdom, Taiwan, Turkey, Germany, Canada, France, Israel, Poland, Croatia, Korea, Republic of, Ireland, Russian Federation, Singapore, Sw...
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, Spain, Czechia, Taiwan, Italy, Japan, New Zealand, Poland, Hungary, United States, United Kingdom, Australia, Romania, Portugal, Korea, Republic of, Russian Federation, Austria, Brazil, Bulgaria, France, Ireland
Dana-Farber Cancer Institute
Genentech, Inc.; Biogen

Completed

Rituximab for Prevention of Chronic GVHD

Hematological Malignancies

United States
Prof. Dr. Wolfgang Hiddemann
Hoffmann-La Roche; Mundipharma Research GmbH & Co KG

Completed

First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years (GABe2016)

Indolent Non-hodgkin Lymphoma

Germany
Fondazione Italiana Linfomi ONLUS

Completed

Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma

Follicular Non-Hodgkin's Lymphoma

Italy
BeiGene

Active, not recruiting

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, China, Taiwan, Belgium, France, United Kingdom, Spain, New Zealand, Australia, Czechia, Italy, Poland, Russian Federation, Sweden, Austria
Eagle Pharmaceuticals, Inc.

Completed

A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients

Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate

United States
SymBio Pharmaceuticals

Completed

A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Japan
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

GIMEMA CLL0809 Study (BendOfa) (BendOfa)

Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or | Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines

Italy
Shandong Lanjin Pharmaceuticals Co.,Ltd

Unknown

Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma by Clinical Course

China
Mayo Clinic

Completed

Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Refractory Multiple Myeloma

United States
Nevada Cancer Institute
GlaxoSmithKline; Cephalon

Withdrawn

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

Chronic Lymphocytic Leukemia (CLL)

United States
Novartis Pharmaceuticals

Terminated

Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy (A+B)

Lymphoma, Follicular

United States, Belgium, Italy, Hong Kong, Austria, Germany, Japan, Russian Federation, United Kingdom, Canada, Slovakia, Poland, Ukraine, Puerto Rico, Greece, France, Argentina
German CLL Study Group
Gilead Sciences; Novartis Pharmaceuticals

Completed

Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

Chronic Lymphocytic Leukemia

Germany
Cephalon

Completed

Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab

Non-Hodgkin's Lymphoma

United States, Canada, Puerto Rico
Cephalon

Completed

Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy

Malignancy

Netherlands
Nevada Cancer Institute
GlaxoSmithKline; Cephalon

Terminated

Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab

Chronic Lymphocytic Leukemia (CLL)

United States
SymBio Pharmaceuticals

Completed

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

Japan
Novartis Pharmaceuticals

Completed

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

Lymphoma, Non-Hodgkin

United States
Grupo Español de Linfomas y Transplante Autólogo...

Completed

Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL). (BeEAM2010-01)

Bendamustine | Conditioning Therapy | Autologous Stem Cell Transplant | Aggressive Non Hodgkin's Lymphoma

Spain
Lundbeck Canada Inc.

Completed

Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia (BENDACT)

Chronic Lymphocytic Leukemia | Indolent Non-Hodgkin's Lymphoma

Canada
Millennium Pharmaceuticals, Inc.

Terminated

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

United States, Canada
Jiangsu Simcere Pharmaceutical Co., Ltd.

Completed

Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

China
Washington University School of Medicine

Completed

Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
German Breast Group

Completed

A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer (RiTa)

Metastatic Breast Cancer
University of Washington
National Cancer Institute (NCI)

Completed

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma | Relapsed T-Cell Lymphoma | Refractory T-Cell Lymphoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Lung Cancer

United States
French Innovative Leukemia Organisation
Mundipharma Pte Ltd.

Completed

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma (BENTLY)

T-cell Lymphoma

France
WiSP Wissenschaftlicher Service Pharma GmbH
Mundipharma Research GmbH & Co KG; Klinikum Leverkusen gGmbH; ribosepharm GmbH

Completed

Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
Fate Therapeutics

Recruiting

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Advanced Solid Tumor

United States
Celgene

Active, not recruiting

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

Neoplasms

United States, France, Australia, Canada, Italy, Korea, Republic of, Spain, United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

EBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditions

United States
St. Petersburg State Pavlov Medical University
N.N. Petrov National Medical Research Center of Oncology

Recruiting

Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma (Prolgo-HL)

Hodgkin Lymphoma

Russian Federation
Sidney Kimmel Cancer Center at Thomas Jefferson...

Withdrawn

Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma

Multiple Myeloma | Plasma Cell Leukemia

United States
Peter Moosmann
Kantonsspital Aarau

Completed

Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

Lymphoma, Non-Hodgkin
Novartis Pharmaceuticals

Completed

Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma

Cancer

United States
SCRI Development Innovations, LLC
GlaxoSmithKline; Novartis; Cephalon

Completed

Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy

Diffuse Large B-Cell Lymphoma

United States
Fondazione Italiana Linfomi ONLUS

Completed

A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma (IIL INFL09)

Non-Hodgkin's Lymphoma | Indolent Non-follicular

Italy
Zhengzhou University

Recruiting

A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma

Newly Diagnosed Mantle Cell Lymphoma

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Lymphoma | Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Lymphocytic Neoplasm

United States
Celgene

Completed

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)

Lymphoma | Leukemia, Lymphocytic, Chronic, B-Cell

United States, United Kingdom, Germany, France, Italy, Netherlands, Japan
TG Therapeutics, Inc.

Terminated

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma

United States, Poland, Australia, Italy, United Kingdom, Israel, Korea, Republic of, Slovakia, Spain
Arbeitsgemeinschaft medikamentoese Tumortherapie
Mundipharma Pte Ltd.

Completed

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell

Austria
University of Liverpool
GlaxoSmithKline; Chugai Pharma USA; Napp Pharmaceuticals Limited

Unknown

A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment (RIAltO)

Chronic Lymphocytic Leukaemia

United Kingdom
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditions

United States
M.D. Anderson Cancer Center
National Comprehensive Cancer Network; Cephalon

Completed

Bendamustine and Bevacizumab for Advanced Cancers

Advanced Cancer

United States
Hoffmann-La Roche

Completed

A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Spain

Search clinical trials for: Rituximab-Bendamustine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations